MET (MET proto-oncogene, receptor tyrosine kinase)

These results indicate c-Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c-Met status. As targeted therapies may elevate c-Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c-Met negative.

P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028

Aspyre Clinical Test for Lung performs effectively on samples derived from fine needle aspirate rinses and pleural fluid. Using these cytology-based specimens for biomarker testing enables pathologists to perform simplified genomic profiling while preserving valuable tissue specimens, potentially reducing the need for additional invasive procedures.

This case underscores dynamic clonal evolution in advanced NSCLC: the initial L747S/L858R clone showed Osimertinib sensitivity, while subsequent resistance revealed a distinct profile (distinct TP53 mutation, MET amplification, high PD-L1/TMB) that explained the durable response to Pembrolizumab. These findings provide crucial evidence for sequential therapy strategies in compound EGFR mutations. Our findings also highlight the utility of Next Generation Sequencing (NGS) in identifying targetable resistance mechanisms, enabling prolonged survival in patients with compound EGFR mutations and offering valuable insights for clinical decision-making.

P2, N=145, Completed, Beijing Pearl Biotechnology Limited Liability Company | Trial completion date: Dec 2025 --> Jun 2025 | Active, not recruiting --> Completed

Furthermore, the review discusses several shared and interconnected therapeutic targets that have been explored in combination or hybrid strategies with PARP or HDAC inhibition, including tubulin, proteasome, EGFR, VEGFR2, CDKs, topoisomerase I and II, EZH2, BRD4, and c-MET. Understanding these interconnected pathways may facilitate the development of next-generation multitarget anticancer agents with improved efficacy and reduced resistance.

They showed high success rates (98%) for FFPE tissue, whereas liquid biopsy tests had lower rates (37.5% in 2022, 63% in 2024), primarily due to low allelic fractions and intronic deletions. This study highlights the importance of analyzing both DNA and RNA, urging improvements in sensitivity, coverage and bioinformatics.

Moreover, comprehensive in vitro and in vivo experiments demonstrate that nitidine significantly inhibits tumor progression through an LRPPRC-MET-G4-dependent mechanism. Collectively, our study suggests an epigenetic regulatory mechanism involving LRPPRC-MET-G4-mediated MET upregulation and provides a promising therapeutic strategy for MET-driven tumors using molecular glues that target the LRPPRC-MET-G4 interface.

P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027

These findings highlight non-tobacco environmental exposures in young lung cancer and support further investigation of dietary patterns and hormonal factors in mutation-specific disease pathways.

P=N/A, N=3400, Not yet recruiting, AstraZeneca

B7-H3 was identified as the only consistently and strongly expressed surface antigen in a clinically heterogeneous MTC cohort. These findings identify B7-H3 as a potential therapeutic opportunity for advanced MTC and underscore the limited number of targetable surface antigens in this disease.